{"url_path":"/sec/lpcn/8-k/2026-05-19/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1535955/0001493152-26-024365-index.html","accession_number":"0001493152-26-024365","cik":"0001535955","ticker":"LPCN","issuer_name":"Lipocine Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1535955/0001493152-26-024365-index.html","primary_entity_key":"0001535955","primary_entity_name":"Lipocine Inc."},"word_count":100,"has_tables":true,"body_markdown":"**Item\n9.01**\n**Financial\nStatements and Exhibits.**\n\n \n\n(d)\nExhibits\n\n \n\nThe\nfollowing exhibits are filed with this report:\n\n \n\nExhibit\nNo.\n \nDescription\n\n \n \n \n\n99.1\n \n[Press Release announcing Lipocine LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting](ex99-1.htm)\n\n \n \n \n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n \nLIPOCINE\nINC.\n\n \n \n \n \n\nDate:\nMay\n19, 2026\nBy:\n*/s/\nMahesh V. Patel*\n\n \n \n \nMahesh\nV. Patel\n\n \n \n \nPresident\nand Chief Executive Officer"}